Wen Ziying, Ma Rui, Chen Jia, Deng Yujie, Li Huan, Huang Boyong, Han Fengxia, Li Cui, Chen Yang, Wang Hao, Leng Sean X, Sun Shiren, Ning Xiaoxuan
Department of Postgraduate Student, Xi'an Medical University, Xi'an, Shaanxi, 710021, China; Department of Geriatrics, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Department of Geriatrics, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.
Neuroscience. 2025 Jan 26;565:172-181. doi: 10.1016/j.neuroscience.2024.11.036. Epub 2024 Nov 30.
Delirium is one of the serious neurological complications of Coronavirus Disease 2019 (COVID-19) and is associated with significant morbidity and mortality in patients with COVID-19, especially in older patients. There is currently no meta-analysis of risk factors for delirium in patients with COVID-19. This study aimed to identify potential risk factors for delirium in patients with COVID-19 through a meta-analysis of observational clinical studies. In conducting this analysis, literature searches were conducted in PubMed, Embase, Cochrane Library, and Web of Science, and study quality was assessed using the Newcastle-Ottawa Quality Scale (NOS). Data were extracted independently by two reviewers and pooled using either fixed effects or random effects models based on the results of heterogeneity testing. As a result of this meta-analysis, a total of 21 studies were included, including 10,147 patients. The analysis revealed the identification of 26 predisposing factors and 54 precipitating factors associated with COVID-19-related delirium. Notably, the administration of hydrocortisone and azithromycin, among other specific medications designated for COVID-19, exhibited a potential to be positively associated with the incidence of delirium in patients afflicted with COVID-19. In conclusion, the present study identified potential predisposing and precipitating factors linked with delirium in COVID-19 patients. It is anticipated that these results will have a considerable impact on the management and treatment of delirium in COVID-19 patients.
谵妄是2019冠状病毒病（COVID-19）严重的神经并发症之一，与COVID-19患者的高发病率和死亡率相关，尤其是老年患者。目前尚无关于COVID-19患者谵妄危险因素的荟萃分析。本研究旨在通过对观察性临床研究的荟萃分析，确定COVID-19患者谵妄的潜在危险因素。在进行这项分析时，我们在PubMed、Embase、Cochrane图书馆和科学网进行了文献检索，并使用纽卡斯尔-渥太华质量量表（NOS）评估研究质量。由两名 reviewers 独立提取数据，并根据异质性检验结果使用固定效应或随机效应模型进行汇总。作为这项荟萃分析的结果，共纳入了21项研究，包括10147名患者。分析发现了26个与COVID-19相关谵妄相关的诱发因素和54个促发因素。值得注意的是，在为COVID-19指定的其他特定药物中，氢化可的松和阿奇霉素的使用与COVID-19患者谵妄的发生率呈正相关。总之，本研究确定了与COVID-19患者谵妄相关的潜在诱发因素和促发因素。预计这些结果将对COVID-19患者谵妄的管理和治疗产生重大影响。
